The Experts below are selected from a list of 261 Experts worldwide ranked by ideXlab platform
Aikaterini A. Mouza - One of the best experts on this subject based on the ideXlab platform.
-
the effect of surfactant addition on the performance of a bubble column containing a non newtonian liquid
Chemical Engineering Research & Design, 2015Co-Authors: A.d. Passos, Victor Voulgaropoulos, Spiros V. Paras, Aikaterini A. MouzaAbstract:Abstract The purpose of this work is to investigate how the addition of an organic surface Active Agent affects the characteristics of a bubble column equipped with a porous sparger and containing a non-Newtonian liquid. Water and an aqueous glycerin solution, both containing a minute amount of xanthan gum, were the non-Newtonian shear thinning liquids, while the gas phase was atmospheric air for all cases. Small amounts of the non-ionic surface Active Agent Triton X-100 was added to modify the surface tension of the non-Newtonian solutions. The results show that the diameter of the bubbles decreases and the transition point from the homogeneous to the heterogeneous is shifted to higher gas flow rates, when the surfactant is added. Appropriate correlations are also proposed, which take into account the liquid phase properties, the gas phase flow rate, as well as the column and sparger characteristics and predict with reasonable accuracy the transition point from the homogenous to the heterogeneous regime, the Sauter mean diameter of the bubbles and the average gas holdup.
Chen Lin - One of the best experts on this subject based on the ideXlab platform.
-
effect of surface Active Agent on thermal properties of carbonate salt carbon nanomaterial composite phase change material
Applied Energy, 2015Co-Authors: Y B Tao, Chen LinAbstract:Surface Active Agent (SAA) was used to improve nanomaterial dispersion during preparation process of carbonate salt/nanomaterial composite phase change material (CPCM) by solution evaporation method. In order to investigate the effects of SAA on CPCM thermal performance, three kinds of PCM samples were prepared and their thermal performances were characterized. The results show that nanomaterial dispersion greatly affects CPCM thermal performance. For CPCM without SAA, its thermal performance is weakened instead of enhanced due to nanomaterial aggregation and the weakening phenomenon is more obvious when nanomaterial has larger specific surface area. SAA decomposes during high temperature CPCM working process. And the effect of SAA on CPCM thermal performance has duality: on the positive side, SAA can improve nanomaterial dispersion and enhance CPCM thermal performance; on the negative side, SAA decomposition products may weaken CPCM thermal performance. So, SAA and its mass fraction should be carefully selected. Sodium dodecyl sulfate (SDS) is a better SAA for high temperature nano-CPCM and a high mass ratio of SDS to nanomaterial is recommended. With mass ratio of SAA to nanomaterial 10:1, PCM thermal conductivity can be enhanced up to 58.75% by adding 1wt.% multi-walled carbon nanotubes.
C Gonzalez - One of the best experts on this subject based on the ideXlab platform.
-
irinotecan is an Active Agent in untreated patients with metastatic colorectal cancer
Journal of Clinical Oncology, 1996Co-Authors: John A Conti, Nancy E Kemeny, Leonard Saltz, Ying Huang, William P Tong, Tingchao Chou, Ming Sun, S Pulliam, C GonzalezAbstract:PURPOSETo determine the response rate, survival, and toxicity of the new anticancer Agent, irinotecan (CPT-11), in the treatment of metastatic colorectal cancer.PATIENTS AND METHODSForty-one chemotherapy-naive patients with measurable metastatic colorectal cancer were treated with a 90-minute infusion of irinotecan 125 mg/m2 administered weekly for 4 weeks every 6 weeks. Pretreatment tumor biopsies to assess topoisomerase-I (Topo-I) activity were obtained from 11 patients. The pharmacokinetics for irinotecan and its Active metabolite, SN-38, were determined in 18 patients.RESULTSThirteen of 41 patients (32%) had a partial response (PR; 95% confidence interval, 18% to 46%). The median response duration was 8.1 months (range, 4.0 to 16.0) and the median survival time was 12.1 months (range, 2.1 to 21.7) for all 41 patients. Grade 3 or 4 toxicities were diarrhea (29% of patients) and neutropenia (22% of patients). Grade 3 or 4 diarrhea was substantially more prevalent in the initial 18 patients on study, wit...
Zhu Wei - One of the best experts on this subject based on the ideXlab platform.
-
effect of surface Active Agent on pvc plastisol in rotational molding
Plastics Science and Technology, 1999Co-Authors: Zhu WeiAbstract:In this paper,by studying the type and quantity of surface Active Agent affecting on the property of PVC plastisol in more detail,finally the type and quantity of surface Active Agent are defined.
Dah H Ho - One of the best experts on this subject based on the ideXlab platform.
-
antimicrobial activity of a novel des fluoro 6 quinolone garenoxacin bms 284756 compared to other quinolones against clinical isolates from cancer patients
Diagnostic Microbiology and Infectious Disease, 2002Co-Authors: Kenneth V. I. Rolston, Susan Frisbeehume, Barbara Leblanc, Harriet Streeter, Dah H HoAbstract:Abstract The in vitro spectrum of a novel des-fluoro (6) quinolone, garenoxacin (BMS-284756), was compared with that of ciprofloxacin, levofloxacin, and trovafloxacin against 736 clinical isolates from cancer patients. Garenoxacin was the most Active Agent overall against Gram-positive organisms, with potent activity against Aerococcus spp., Micrococcus spp., Rhodococcus equi , Stomatococcus mucilaginous , Bacillus spp., Enterococcus faecalis , Listeria monocytogenes , methicillin-susceptible Staphylococcus spp., and all β-hemolytic and viridans streptococci. Although ciprofloxacin was the most Active Agent tested against the Enterobacteriaceae garenoxacin inhibited the majority of these isolates at ≤4.0 μg/ml, its proposed susceptibility break-point. All 4 Agents had sub-optimal activity against Pseudomonas aeruginosa and variable activity against other non-fermenters, with Stenotrophomonas maltophila and Alcaligenes spp. being the most resistant isolates. The overall broad spectrum of garenoxacin warrants its evaluation for the prevention or treatment of infections in cancer patients.